| Literature DB >> 36234487 |
Siavash Iravani1, Rajender S Varma2.
Abstract
MXenes encompass attractive properties such as a large surface area, unique chemical structures, stability, elastic mechanical strength, excellent electrical conductivity, hydrophilicity, and ease of surface functionalization/modifications, which make them one of the broadly explored two-dimensional materials in the world. MXene-based micro- and nanocomposites/systems with special optical, mechanical, electronic, and excellent targeting/selectivity features have been explored for cancer nanotheranostics. These materials exhibit great diagnostic and therapeutic potential and offer opportunities for cancer photoacoustic imaging along with photodynamic and photothermal therapy. They can be applied to targeted anticancer drug delivery while being deployed for the imaging/diagnosis of tumors/cancers and malignancies. MXene-based systems functionalized with suitable biocompatible or bioactive agents have suitable cellular uptake features with transferring potential from vascular endothelial cells and specific localization, high stability, and auto-fluorescence benefits at different emission-excitation wavelengths, permitting post-transport examination and tracking. The surface engineering of MXenes can improve their biocompatibility, targeting, bioavailability, and biodegradability along with their optical, mechanical, and electrochemical features to develop multifunctional systems with cancer theranostic applications. However, challenges still persist in terms of their environmentally benign fabrication, up-scalability, functionality improvement, optimization conditions, surface functionalization, biocompatibility, biodegradability, clinical translational studies, and pharmacokinetics. This manuscript delineates the recent advancements, opportunities, and important challenges pertaining to the cancer nanotheranostic potential of MXenes and their derivatives.Entities:
Keywords: MXene-based composites; MXenes; cancer diagnostics; cancer therapeutics; nanotheranostics
Year: 2022 PMID: 36234487 PMCID: PMC9565327 DOI: 10.3390/nano12193360
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.719
Figure 1MXenes with cancer nanotheranostic applications.
Some selected examples of MXenes for cancer nanotheranostics.
| MXenes | Applications | Advantages/Benefits | Refs. |
|---|---|---|---|
| Ta4C3 | Dual-mode photoacoustic/computed tomography (CT) imaging along with effective photothermal ablation of tumors (in vivo) |
Excellent photothermal conversion efficiency (η = ~44.7%) Targeted photothermal ablation of tumors (in vitro and in vivo) | [ |
| Ti3C2 | Cancer theranostics; photothermal elimination of cancerous cells and ablation of tumors; magnetic resonance imaging (MRI) of tumors |
Significant T2 relaxivity (~394.2 mM−1 s−1) with efficient contrast-enhanced MRI Excellent photothermal conversion efficiency (~48.6%) with high biocompatibility | [ |
| Ti3C2 | Photothermal cancer nanotherapy with MR/CT imaging capabilities towards tumor cells or xenografts; applications of GdW10@Ti3C2 nanocomposites as CT contrast agents |
High biocompatibility (in vivo) Deep penetration and high spatial resolution of CT images effective accumulation in tumor tissues; high photothermal ablation efficacy (in vivo) High stability (in vivo) with suitable photothermal conversion efficiency (η = ~21.9%) | [ |
| Ti3C2 | MR and photoacoustic dual-modality imaging-guided photothermal cancer therapy |
High biocompatibility (in vivo) Good photothermal conversion performance (~22.9%) Efficient tumor ablation and tumor growth suppression | [ |
| Ti3C2 | Dual-modal NIR-II/MRI-guided tumor hyperthermia |
Efficient T2-weighted MRI High photothermal conversion efficiency (~43.62% at 808 nm irradiation) High photothermal stability and effects Efficient tumor ablation (the inhibition ratio was ~92.9%) | [ |
| Ti3C2 | Photothermal cancer therapy; photoacoustic imaging capabilities |
Suitable photothermal effects upon NIR-II light irradiation with a low power density (0.75 W cm−2) Efficient nanosystems for hyperthermia-amplified nanozyme catalytic therapy | [ |
| Mo2C | Phototherapy of tumor/cancer using multi-modal imaging-guided strategy |
High biocompatibility Minimal toxicity and hematotoxicity | [ |
| Nb2C | Chemo/photothermal cancer therapy; diagnostic potential |
Targeted chemotherapy with reduced toxicity Improved photothermal hyperthermia of cancer Low/noncytotoxicity (at 300 μg mL−1) The photothermal conversion efficiency was ~28.6% | [ |
| Ta4C3 | Photothermal therapy and photoacoustic imaging of cancers with contrast-enhanced properties |
Excellent growth suppression of tumor No noticeable toxicity No noticeable histological defects or lesions in the organs The efficiency of photothermal conversion was ~34.9% | [ |
| Ta4C3 | MRI/CT imaging guided photothermal breast cancer therapy |
Excellent photothermal ablation of breast tumors No noticeable toxicity with good biocompatibility The efficiency of photothermal conversion was ~32.5% | [ |
| Ti3C2 | MRI/CT imaging guided photothermal cancer therapy |
No noticeable cell necrosis Low toxicity with good biocompatibility The efficiency of photothermal conversion was ~21.9% |
[ |
| V2C | MR/photoacoustic guided photothermal cancer treatment |
No noticeable adverse side effects with good biocompatibility Excellent ablation of tumors The efficiency of photothermal conversion was ~45.05% | [ |
| V2C | MR/photoacoustic guided photothermal cancer treatment |
Low toxicity with good biodistribution The efficiency of photothermal conversion was ~48 % | [ |
| Ti3C2 | Photoacoustic/CT guided photothermal cancer treatment |
High stability with good biocompatibility; Low long-term toxicity Core–shell nanocomposites with efficient cancer therapeutic potential | [ |
Figure 2(A,B) The preparative process of MXene nanosheets including hydrogen fluoride (HF) etching and sonication and their surface functionalization/modification using MnOx and soybean phospholipid (SP). (C) MXene-based nanocomposites with photoacoustic (PA), MR, and CT imaging capabilities combined with photothermal effects for tumor ablation. Adapted from Reference [60] with permission. Copyright: 2017, American Chemical Society.
Figure 3The preparative process of bovine serum albumin (BSA)-modified W1.33C i-MXene with high photothermal conversion efficacy for theranostic applications (multimodal imaging and photothermal therapy). CT: computed tomography; PTT: photothermal therapy; and PAI: photoacoustic imaging. Adapted from Reference [77] with permission (CC BY). Copyright: 2021, Wiley-VCH GmbH.
Figure 4(A) The preparative process of NaErF4@Ti3C2 MXene-based nanosystems for cancer theranostic applications. (B) Photothermal therapy and MR/NIR-II b imaging of cancer/tumor using the MXene nanocomposites. Adapted from Reference [56] with permission. Copyright: 2022, American Chemical Society.